

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202jxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26 MARPAT enhanced with FSORT command
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
NEWS 5 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 6 DEC 01 ChemPort single article sales feature unavailable
NEWS 7 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATEM
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:50:40 ON 02 FEB 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 18:51:02 ON 02 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 FEB 2009 HIGHEST RN 1099320-21-4
DICTIONARY FILE UPDATES: 1 FEB 2009 HIGHEST RN 1099320-21-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590064.str



chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 6
chain bonds :
1-13 5-7 7-8 7-12 8-9 9-10 10-11 13-14 14-15 15-16 16-17 17-18 18-19
18-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-8 7-12 8-9 10-11 18-19 18-20
exact bonds :
1-13 5-7 9-10 13-14 14-15 15-16 16-17 17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 18:51:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 8 TO 329

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 18:51:42 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 152 TO ITERATE

100.0% PROCESSED 152 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01

L3

5 SEA SSS FUL L1

```
=> d l3 ibib ab hitstr tot
'IBIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'AB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
```

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

```
REG      - RN
SAM      - Index Name, MF, and structure - no RN
FIDE     - All substance data, except sequence data
IDE      - FIDE, but only 50 names
SQIDE    - IDE, plus sequence data
SQIDE3   - Same as SQIDE, but 3-letter amino acid codes are used
SQD      - Protein sequence data, includes RN
SQD3     - Same as SQD, but 3-letter amino acid codes are used
SQN      - Protein sequence name information, includes RN
```

```
EPROP   - Table of experimental properties
PPROP   - Table of predicted properties
PROP    - EPROP, ETAG, PPROP and SPEC
```

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

```
ABS  -- Abstract
APPS -- Application and Priority Information
BIB  -- CA Accession Number, plus Bibliographic Data
CAN  -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND  -- Index Data
IPC  -- International Patent Classification
PATS -- PI, SO
STD  -- BIB, IPC, and NCL
```

```
IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented
```

```
OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels
```

```
SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations
```

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.

HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):delet
'DELET' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

EPROP - Table of experimental properties
PPROP - Table of predicted properties
PROP - EPROP, ETAG, PPROP and SPEC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):end

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	186.84	187.06

FILE 'CAPLUS' ENTERED AT 18:52:55 ON 02 FEB 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Feb 2009 VOL 150 ISS 6
 FILE LAST UPDATED: 1 Feb 2009 (20090201/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 2 L3

=> d l4 ibib ab hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1230515 CAPLUS

DOCUMENT NUMBER: 148:69663

TITLE: Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat

AUTHOR(S): Hoi, P. M.; Visintin, C.; Okuyama, M.; Gardiner, S. M.; Kaup, S. S.; Bennett, T.; Baker, D.; Selwood, D. L.; Hiley, C. R.

CORPORATE SOURCE: Department of Pharmacology, University of Cambridge, Cambridge, UK

SOURCE: British Journal of Pharmacology (2007), 152(5), 751-764

CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A putative novel cannabinoid receptor mediates vasorelaxation to anandamide and abnormal-cannabidiol and is blocked by O-1918 and by high concns. of rimonabant. This study investigates VSN16, a novel water-soluble agonist, as a vasorelaxant potentially acting at non-CB1, non-CB2 cannabinoid receptors in the vasculature. VSN16 and some analogs were synthesized and assayed for vasodilator activity in the rat third generation mesenteric artery using wire myog. Also carried out with VSN16 were hemodynamic studies in conscious rats and binding studies to CB1 receptors of rat cerebellum. VSN16 relaxed mesenteric arteries in an endothelium-dependent manner. The vasorelaxation was antagonized by high concns. of the classical cannabinoid antagonists, rimonabant and AM 251, as well as by O-1918, an antagonist at the abnormal-cannabidiol receptor but not at CB1 or CB2 receptors. It did not affect [3H]CP55,940 binding to CB1 receptors in rat cerebellum. The vasorelaxation was not pertussis toxin-sensitive but was reduced by inhibition of nitric oxide synthesis, Ca²⁺-sensitive K⁺ channels (KCa) and TRPV1 receptors. In conscious rats VSN16 transiently increased blood pressure and caused a longer-lasting increase in mesenteric vascular conductance. Structure-activity studies on vasorelaxation showed a stringent interaction with the target receptor. VSN16 is an agonist at a novel cannabinoid receptor of the vasculature. It acts on the endothelium to release nitric oxide and activate KCa and TRPV1. As it is water-soluble it might be useful in bringing about peripheral cannabinoid-like effects without accompanying central or severe cardiovascular responses.

IT 960132-68-7P


RL: SPN (Synthetic preparation); PREP (Preparation)

(VSN16R; preparation and vascular pharmacol. of cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-Me-ethyl)benzamide (VSN16) in the rat)

RN 960132-68-7 CAPLUS


CN Benzamide, 3-[(1Z)-6-amino-6-oxo-1-hexen-1-yl]-N-[(1R)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 960132-69-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (VSN16S; preparation and vascular pharmacol. of cannabinoid-like compound,
 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-Me-ethyl)benzamide
 (VSN16) in the rat)
 RN 960132-69-8 CAPLUS
 CN Benzamide, 3-[(1Z)-6-amino-6-oxo-1-hexen-1-yl]-N-[(1S)-2-hydroxy-1-
 methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




IT 863713-78-4P, VSN 16
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation and vascular pharmacol. of cannabinoid-like compound,
 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-Me-ethyl)benzamide
 (VSN16) in the rat)
 RN 863713-78-4 CAPLUS
 CN Benzamide, 3-[(1Z)-6-(dimethylamino)-6-oxo-1-hexen-1-yl]-N-(2-hydroxy-1-
 methylethyl)- (CA INDEX NAME)

Double bond geometry as shown.



IT 863713-82-0P 863713-84-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and vascular pharmacol. of cannabinoid-like compound,
 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-Me-ethyl)benzamide
 (VSN16) in the rat)
 RN 863713-82-0 CAPLUS
 CN Benzamide, 3-[(1Z)-6-amino-6-oxo-1-hexen-1-yl]-N-(2-hydroxy-1-methylethyl)-
 (CA INDEX NAME)


Double bond geometry as shown.



RN 863713-84-2 CAPLUS

CN Benzamide, N-(2-hydroxy-1-methylethyl)-3-[(1Z)-6-(methylamino)-6-oxo-1-hexen-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

47

THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:962195 CAPLUS
 DOCUMENT NUMBER: 143:266679
 TITLE: Preparation of benzamide derivatives as cannabinoid
 receptor modulators
 INVENTOR(S): Okuyama, Masahiro; Selwood, David; Visintin, Cristina;
 Baker, David; Pryce, Gareth
 PATENT ASSIGNEE(S): University College London, UK
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080316	A2	20050901	WO 2005-GB605	20050221
WO 2005080316	A3	20051103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005214146	A1	20050901	AU 2005-214146	20050221
CA 2556940	A1	20050901	CA 2005-2556940	20050221
EP 1745011	A2	20070124	EP 2005-708399	20050221
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1956946	A	20070502	CN 2005-80012480	20050221
BR 2005007914	A	20070710	BR 2005-7914	20050221
JP 2007523150	T	20070816	JP 2006-553673	20050221
MX 2006009433	A	20070321	MX 2006-9433	20060818
IN 2006DN04772	A	20070831	IN 2006-DN4772	20060821
NO 2006004227	A	20061116	NO 2006-4227	20060919
US 20080114062	A1	20080515	US 2007-590064	20071002
PRIORITY APPLN. INFO.:			GB 2004-3864	A 20040220
			WO 2005-GB605	W 20050221

OTHER SOURCE(S): CASREACT 143:266679; MARPAT 143:266679

AB Title compds. I [wherein Z = OR1 or NR1R2; R1, R2 = H or hydrocarbyl group; X = (un)substituted alkylene, alkenylene or alkynylene; Y = OH, NO2, CN, etc.; A = (un)substituted aryl or heteroaryl; B = (CH2)n; n = 0-5, with some limitations, or pharmaceutically acceptable salts thereof] were prepared as cannabinoid receptor modulators. For instance, synthesis of II was achieved from 3-iodobenzoic acid via (1) EDCI-mediated condensation with alaninol to an amide (34%), (2) Pd-catalyzed Songashira coupling of the resultant iodide with 5-hexynoic acid to a phenylacetylene (99%), (3) amidation with Me2NH·HCl (96%), and (4) Lindlar hydrogenation. A number of biol. assays were performed, and some results were graphed and discussed. II was demonstrated to be an agonist toward the CB1 receptor with an IC50 of .apprx. 0.1 nM, vs. .apprx. 5 nM for reference (R)-Win 55212. Therefore, I and their pharmaceutical compns. are potentially useful for the treatment of muscular and gastrointestinal disorders, or for controlling spasticity or tremors.

IT 863713-82-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (modulator; preparation of benzamide derivs. as cannabinoid receptor modulators)

RN 863713-82-0 CAPLUS

CN Benzamide, 3-[(1Z)-6-amino-6-oxo-1-hexen-1-yl]-N-(2-hydroxy-1-methylethyl)- (CA INDEX NAME)

Double bond geometry as shown.




IT 863713-78-4P 863713-84-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (modulator; preparation of benzamide derivs. as cannabinoid receptor modulators)

RN 863713-78-4 CAPLUS

CN Benzamide, 3-[(1Z)-6-(dimethylamino)-6-oxo-1-hexen-1-yl]-N-(2-hydroxy-1-methylethyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 863713-84-2 CAPLUS

CN Benzamide, N-(2-hydroxy-1-methylethyl)-3-[(1Z)-6-(methylamino)-6-oxo-1-hexen-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

15.28

202.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.64

-1.64

STN INTERNATIONAL LOGOFF AT 18:57:57 ON 02 FEB 2009